promises and challenges in up-and-coming cll therapies
Published 6 years ago • 254 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
2:32
challenges with implementing cars in cll and the promise of allogeneic products
-
2:10
a study investigating the incidence of treatment-emergent autoimmune cytopenias in cll
-
3:37
challenges and unmet needs in mpns: transplant decision-making and the management of mpn-ap/bp
-
1:34
the mutational profile in patients with cll treated with acalabrutinib or ibrutinib
-
2:46
challenges in the use of btk inhibitors for cll
-
5:19
a 17-year fight against multiple myeloma
-
2:53
triplet regimens for treating multiple myeloma at early relapse
-
5:01
keynote-522: final os findings of pembrolizumab and chemotherapy in tnbc
-
1:33
all diagnostics: challenges and considerations
-
1:10
the importance of incorporating patient-reported outcomes in clinical practice
-
0:38
pain management for patients with scd and thalassemia in lebanon
-
2:10
challenges in treating patients with hl who relapse after autosct & novel therapies being explored
-
2:48
the promise of pyruvate kinase activators, such as mitapivat, for treating scd and thalassemia
-
1:20
improving patient outcomes in ctcl: clinical collaboration and novel agents
-
1:20
clinical implications of persisting preleukemic clones in remission in acute myeloid leukemia (aml)
-
1:40
challenges in monitoring for cardiotoxicity when treating patients with cll
-
0:51
challenges in managing myeloma patients
-
2:41
btk and plcg2 mutations in cll patients taking ibrutinib
-
2:24
prevalence of btk and plcγ2 mutations in cll relapsing under ibrutinib
-
4:25
cll: state of the art in italy
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
1:22
the promise of menin inhibition in aml